The Journal of Studies on Alcohol and Drugs is a premier academic journal dedicated to advancing the understanding of alcohol and drug use, its effects, and its societal implications. Published by ALCOHOL RES DOCUMENTATION INC at the Center for Alcohol Studies, Rutgers University, this journal features comprehensive research that spans the disciplines of health, psychiatry, mental health, and toxicology. With its Q1 ranking in Health (Social Science) and Q2 ranking in Psychiatry and Mental Health, the journal plays a vital role in disseminating high-impact research that informs policy, prevention, and treatment strategies in addiction and substance use. The journal contributes significantly to the field, as evidenced by its solid Scopus rankings and engagement with contemporary issues, making it an essential resource for researchers, practitioners, and students. Although it does not offer open access, the journal's commitment to rigorous peer review and scholarship ensures that it remains at the forefront of research on alcohol and drugs through its converged publication timeline from 2007 to 2024.

Alcoholism Treatment Quarterly is a reputable journal dedicated to advancing the understanding of alcohol use disorders and their treatment. Published by Routledge Journals, Taylor & Francis Ltd, this journal has established itself as an essential resource within the fields of Medicine and Psychiatry and Mental Health, evidenced by its placement in the Q3 category for both disciplines in 2023. With a comprehensive scope covering the multifaceted aspects of alcoholism treatment, the journal serves as a vital platform for researchers, clinicians, and students to share and access high-quality, peer-reviewed articles. Although it is not an open-access journal, it is widely recognized for its contribution to the field, having been in continuous publication since 1984 and looking forward to its 40th anniversary in 2024. The journal aims to promote evidence-based practices and foster discourse on innovative treatment methods and research trends, making it an indispensable asset for anyone involved in the prevention and treatment of alcohol-related issues.

Substance Abuse and Rehabilitation, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the study and treatment of substance abuse and related rehabilitation practices. With its ISSN 1179-8467, this journal provides a vital platform for researchers, clinicians, and students to disseminate their findings and insights in a field increasingly relevant to public health. Since becoming open access in 2010, the journal has enhanced its reach, allowing for a broader audience to engage with cutting-edge research and reviews that address the complexities of substance abuse disorders. The journal aims to foster innovation and interdisciplinary collaboration by publishing high-quality peer-reviewed articles that cover a wide range of topics, including addiction therapy, policy implications, and the social determinants of substance use. As a vital resource within the realm of addiction research, Substance Abuse and Rehabilitation plays a crucial role in driving forward knowledge and practices that can improve outcomes for individuals and communities affected by substance use issues.

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.

DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

Drug and Alcohol Dependence is a premier journal published by Elsevier Ireland Ltd, dedicated to the rigorous exploration and analysis of substance use disorders, including drug and alcohol dependencies. With its established history since 1975 and a remarkable convergence of research extending to 2024, the journal holds a prestigious position within the academic community, evidenced by its Q1 ranking in multiple categories, including Pharmacology, Psychiatry and Mental Health, and Toxicology for 2023. It ranks impressively among its peers, underscored by Scopus rankings of #46, #99, and #27 in key fields related to medical pharmacology and toxicology. As a non-open access title, it caters to a global readership of researchers, professionals, and students, providing them with peer-reviewed insights into critical developments and innovative methodologies in the field. The journal’s commitment to advancing knowledge and understanding of drug and alcohol dependence is essential for addressing the global challenges posed by substance use, making it a valuable resource for all stakeholders in public health and clinical practice.

ADDICTION, published by Wiley, is a highly regarded academic journal that serves the vibrant fields of Medicine and Psychiatry and Mental Health. With an impressive impact factor reflective of its significance—ranking in the top 8% and 7.5% of its categories respectively—this journal is esteemed for its rigorous peer-reviewed research which spans a wide array of topics related to addiction, including pharmacology, prevention, and treatment modalities. Since its inception in 1993, ADDICTION has continually provided a platform for innovative research, shaping the discourse and influencing clinical practices worldwide. This journal, based in the United Kingdom at a prestigious location in Hoboken, NJ, stands as a beacon for researchers, practitioners, and students alike, committed to advancing understanding and strategies to combat addiction-related challenges. Although it is not an Open Access publication, the journal's contribution to the field remains invaluable, ensuring that cutting-edge findings are disseminated widely among professionals dedicated to improving mental health outcomes.

Advances in Dual Diagnosis, published by EMERALD GROUP PUBLISHING LTD, serves as a vital resource for professionals and researchers in the fields of psychiatry and mental health. With an ISSN of 1757-0972 and E-ISSN 2042-8324, this journal has been at the forefront of dual diagnosis research since its inception in 2008, aiming to bridge the gap in knowledge and practice regarding the co-occurrence of mental health disorders and substance use issues. Rated in the Q4 category for Psychiatry and Mental Health, it ranks 31st out of 45 in Nursing and Psychiatric Mental Health and 408th out of 567 in Medicine and Psychiatry, providing a unique platform for showcasing emerging research, innovative treatment strategies, and case studies that enhance understanding of complex patient needs. While the journal is not openly accessible, its contributions are crucial for driving forward the academic discourse and practical applications surrounding dual diagnosis. As we look to the future through 2024 and beyond, the Advances in Dual Diagnosis journal continues to strive for excellence in disseminating knowledge that benefits practitioners and scholars alike.

Welcome to the Journal of Addiction Medicine, a premier academic resource devoted to the field of addiction studies, published by LIPPINCOTT WILLIAMS & WILKINS. Since its inception in 2007, this esteemed journal has become a leader in disseminating groundbreaking research, with impressive rankings in the Q1 quartile across key disciplines such as Medicine (Miscellaneous), Pharmacology (Medical), and Psychiatry and Mental Health, reflecting its significance in the scholarly community. With an ISSN of 1932-0620 and an E-ISSN of 1935-3227, it caters to a diverse audience of researchers, clinicians, and students seeking to expand their understanding of addiction medicine. The journal's articles are primarily published in a non-open access format, ensuring high-quality research is accessible through institutional subscriptions. With a Scopus ranking that positions it within the top tiers of several relevant categories, the Journal of Addiction Medicine is essential for anyone committed to advancing knowledge in the field and addressing the complexities surrounding addiction.